The Efficacy of Potassium-competitive Acid Blocker in Patients With Laryngopharyngeal Reflux Disease
Status:
Completed
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
Background/Aims: Tegoprazan is a novel potassium-competitive acid blocker that has a fast
onset of action and can control gastric pH for a prolonged period, which could offer clinical
benefit in acid-related disorders. We aimed to evaluate whether tegoprazan would be more
effective in controlling symptoms than placebo in patients with laryngopharyngeal reflux
disease (LPRD). Methods: This double-blind, randomized, placebo-controlled trial randomly
assigned 35 patients suffering LPRD symptom to two groups: Tegoprazan50mg once daily and
placebo. The primary end point was complete resolution rate of LPRD symptoms after 8-week
medication, and the secondary endpoints were complete resolution rate of LPRD symptoms after
4-week medication, change of reflux symptom index (RSI) and reflux finding score (RFS) from
baseline at 4- and 8-week medication.